2012美國癌症新藥公司Eureka Therapeutics投資說明會 (2012/4/17)

April 13th, 2012 | Categories: 2012 | Tags:

Eureka Therapeutics 簡介
Eureka Therapeutics最初成立於2006年2月,坐落於美國生物科技產業最活躍的加州灣區,是一間專門做癌症治療用新藥開發的生技公司。 利用其獨創的ALPHATM及MAGETM技術平台,Eureka Therapeutics成功製造出高專一性、高效能的全人原單株抗體。

Eureka Therapeutics優勢
多方位的藥品開發產線 針對多種市場需求,利用新穎的知識與技術,篩選出最具潛力的多種抗癌候選藥物。

  • ALPHATM嗜菌體表現系統 提供全人原化單株抗體藥物的開發平台。
  • MAGETM 抗體Fc優化技術 成功加強抗體對效應作用細胞之功能性。
  • 抗體表達及細胞株研發的優秀專家團隊 完整提供新藥開發所需之知識及技術。

藥物開發流程
採取低風險之新藥開發策略,Eureka 透過獨創的技術平台,有效製造全人原化以及優化的潛力藥物,Eureka的主要研發內容,除了有對市場已知的標靶藥物做進一步的加強改良(Bio-superior),同時也對新標靶藥物的開發。其中進展最迅速之候選藥物已進入FDA的臨床研究申請階段,預計在2013年可進入第一期的人體臨床試驗階段。

以下為Eureka的Bio-superior(MAGE101, MAGE201, MAGE301, MAGE801)以及新標靶藥物(EXT001, ET601, ET602)的開發階段示意圖:
開發階段示意圖

Eureka的bio-superior研發內容主要針對市面上最熱門的其中四個已知的標靶藥物–Trastuzumab ( Roche )、Rituximab ( Roche )、Cetuximab ( Bristol-Myers Squibb/Merk/Eli Lilly ) 以及Alemtuzumab ( Genzyme ) 進行改良,利用MAGETM 抗體Fc優化技術篩選出更高效能的候選藥物。這些藥物在2010年總銷售金額約為美金120億元。

在新藥開發部分,Eureka主要針對全新或之前瞭解有限的癌症標靶抗原,利用ALPHATM及MAGETM 技術平台,研發出其相對應的全人原抗體藥物,這些新研發之候選藥物,不管在生物體內或生物體外都呈現著劃時代藥物治療效果之潛力,也正代表著Eureka對於創新醫療技術的堅持以及對未開發醫療市場的重視,希望未來能在台灣找到合作夥伴並成立JV公司,完成上述Eureka對未來藥物之開發。

COMPANY OVERVIEW

Eureka Therapeutics is a private biotechnology company focused on the discovery and development of monoclonal antibody-based immunotherapies for cancer treatment. We utilize our proprietary fully-human antibody discovery (ALPHATM) and Fc engineering (MAGETM) technology platforms to generate highly-specific, highly-efficacious fully-human antibody drugs. Eureka was founded in February 2006 (incorporated in California) and is headquartered in Emeryville, CA. Key company highlights include:

 Strong pipeline of oncology drug candidates against validated and novel targets
 Proprietary ALPHATM phage display platform for fully-human monoclonal antibody discovery
 Proprietary MAGETM Fc optimization platform for enhancement of antibody effector functions
 Expertise in antibody expression and cell line development to support drug discovery

PIPELINE

Eureka’s de-risked drug development strategy utilizes our proprietary technology platforms to generate fully-human, optimized drug leads. Our portfolio includes bio-superior drugs against validated targets and innovative drugs against novel targets. Eureka’s most advanced antibody program is in final IND-enabling stages and expected to enter Phase I clinical trial in 2013.

Eureka’s bio-superior drug portfolio is comprised of 4 biologic candidates against well-validated cancer targets. These candidates were generated using MAGETM Fc optimization and are improved versions of blockbuster drugs marketed by Roche (Trastuzumab and Rituximab), Bristol-Myers Squibb/ Merck/ Eli Lilly (Cetuximab), and Genzyme (Alemtuzumab). Cumulative sales of these drugs totaled $12billion in 2010.

Eureka’s innovative drug portfolio is comprised of fully-human antibodies against novel or previously inaccessible cancer antigens. These candidates were generated using both the ALPHATM and MAGETM platforms and represent Eureka’s 「first-in-class」 treatments for unmet medical needs. Results from in vitro and in vivo testing of these candidates have confirmed the potential of these revolutionary drug treatments.

A summary of Eureka’s bio-superior (MAGE101, MAGE201, MAGE301, MAGE801) and innovative (EXT001, ET601, ET602) drug programs can be found on the previous page.

主辦單位:經濟部生技醫藥產業發展推動小組 / 美國Eureka Therapeutics

日 期:101年4月17日(週二)14:00~16:00
101年4月18-19日(週三~週四)一對一洽談(時程另洽)
地 點:台北市南港區園區街3號 (南港軟體工業園區F棟) 17樓A室
經濟部生技醫藥產業發展推動小組 會議室

報名方式:網路報名
會議聯絡人:林小姐 (電話:02-26558133 ext.114)

議 程

時間

14:00~14:10

14:10~14:20

長官及貴賓致詞

14:20~15:00

美國Eureka Therapeutics的投資策略介紹

15:00~16:00

QA

|

Referrer Plugin made by Electric Guitars.